WO2008071081A8 - Préparation d'une protéine hybride anticoagulante provoquant un faible saignement et utilisation de cette dernière - Google Patents

Préparation d'une protéine hybride anticoagulante provoquant un faible saignement et utilisation de cette dernière Download PDF

Info

Publication number
WO2008071081A8
WO2008071081A8 PCT/CN2007/003526 CN2007003526W WO2008071081A8 WO 2008071081 A8 WO2008071081 A8 WO 2008071081A8 CN 2007003526 W CN2007003526 W CN 2007003526W WO 2008071081 A8 WO2008071081 A8 WO 2008071081A8
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
preparation
low bleeding
anticoagulant fusion
anticoagulant
Prior art date
Application number
PCT/CN2007/003526
Other languages
English (en)
Chinese (zh)
Other versions
WO2008071081A1 (fr
Inventor
Zuze Wu
Aiping Yu
Chuanling Zhang
Zhongxiong Tang
Original Assignee
Inst Radiation Med Amms Pla
Beijing Sanly Sci Tech Develop
Zuze Wu
Aiping Yu
Chuanling Zhang
Zhongxiong Tang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Radiation Med Amms Pla, Beijing Sanly Sci Tech Develop, Zuze Wu, Aiping Yu, Chuanling Zhang, Zhongxiong Tang filed Critical Inst Radiation Med Amms Pla
Priority to EP07845883A priority Critical patent/EP2103630B1/fr
Priority to US12/519,309 priority patent/US8101379B2/en
Priority to CN2007800463406A priority patent/CN101668778B/zh
Priority to AT07845883T priority patent/ATE533789T1/de
Priority to JP2009540580A priority patent/JP5345069B2/ja
Publication of WO2008071081A1 publication Critical patent/WO2008071081A1/fr
Publication of WO2008071081A8 publication Critical patent/WO2008071081A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6443—Coagulation factor XIa (3.4.21.27)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21027—Coagulation factor XIa (3.4.21.27)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une protéine hybride anticoagulante qui comprend un oligopeptide reconnu et clivé soit par le facteur XIa et le facteur Xa soit par la thrombine et le facteur Xa. Cette invention concerne également le procédé de préparation de la protéine hybride anticoagulante et l'utilisation médicinale de cette dernière.
PCT/CN2007/003526 2006-12-15 2007-12-11 Préparation d'une protéine hybride anticoagulante provoquant un faible saignement et utilisation de cette dernière WO2008071081A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP07845883A EP2103630B1 (fr) 2006-12-15 2007-12-11 Préparation d'une protéine hybride anticoagulante provoquant un faible saignement et utilisation de cette dernière
US12/519,309 US8101379B2 (en) 2006-12-15 2007-12-11 Preparation of low bleeding anticoagulant fusion protein and its use
CN2007800463406A CN101668778B (zh) 2006-12-15 2007-12-11 低出血抗凝血融合蛋白的制备及其应用
AT07845883T ATE533789T1 (de) 2006-12-15 2007-12-11 Herstellung von mit geringen blutungen assoziiertem gerinnungshemmendem fusionsprotein und dessen verwendung
JP2009540580A JP5345069B2 (ja) 2006-12-15 2007-12-11 低出血性抗凝固性融合タンパク質の調製および使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610165756 2006-12-15
CN200610165756.7 2006-12-15

Publications (2)

Publication Number Publication Date
WO2008071081A1 WO2008071081A1 (fr) 2008-06-19
WO2008071081A8 true WO2008071081A8 (fr) 2009-08-13

Family

ID=39511252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/003526 WO2008071081A1 (fr) 2006-12-15 2007-12-11 Préparation d'une protéine hybride anticoagulante provoquant un faible saignement et utilisation de cette dernière

Country Status (6)

Country Link
US (1) US8101379B2 (fr)
EP (1) EP2103630B1 (fr)
JP (1) JP5345069B2 (fr)
CN (1) CN101668778B (fr)
AT (1) ATE533789T1 (fr)
WO (1) WO2008071081A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045503A1 (fr) 2004-10-19 2006-05-04 Lonza Ag Procede de synthese de peptides en phase solide
CN102180973B (zh) * 2011-03-18 2012-08-29 重庆大学 靶向多功能防栓融合蛋白及其制备方法和应用
CN109206522B (zh) * 2017-07-07 2021-11-09 北京三有利和泽生物科技有限公司 一种长效抗凝血融合蛋白及其应用
CN115572329B (zh) * 2021-06-21 2024-02-06 王大勇 一组活性增强代谢较慢的菲牛蛭基因重组水蛭素及其制备方法
CN113956339B (zh) * 2021-10-28 2023-02-24 中国药科大学 宽体金线蛭抗凝血因子XIa多肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759542A (en) * 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
PT833848E (pt) * 1995-06-12 2002-01-30 Sanquin Bloedvoorziening Peptidos ligantes do factor ix derivados do factor viii e sua utilizacao como inibidores da coagulacao do sangue
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
CN1896108B (zh) * 2005-06-01 2012-01-04 中国人民解放军军事医学科学院放射与辐射医学研究所 特异性抗凝血物质的制备及其应用

Also Published As

Publication number Publication date
CN101668778B (zh) 2012-10-03
CN101668778A (zh) 2010-03-10
US20100113345A1 (en) 2010-05-06
JP5345069B2 (ja) 2013-11-20
EP2103630A1 (fr) 2009-09-23
JP2010512349A (ja) 2010-04-22
EP2103630A4 (fr) 2010-07-28
EP2103630B1 (fr) 2011-11-16
US20100234291A2 (en) 2010-09-16
US8101379B2 (en) 2012-01-24
ATE533789T1 (de) 2011-12-15
WO2008071081A1 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
WO2008030558A3 (fr) Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
WO2006076594A3 (fr) Anticorps et proteines de fusion fc a immunogenicite modifiee
WO2004094475A3 (fr) Anticorps se fixant au facteur tissulaire et leurs utilisations
WO2006127757A3 (fr) Fusion interferon-igg
AU2003299682A1 (en) Device for the determination of blood clotting by capacitance or resistance
DK2256135T3 (da) Proteolytisk spaltbart fusionsprotein, der omfatter en blodkoagulationsfaktor
AU2003226027A1 (en) System for performing blood coagulation assays and measuring blood clotting times
WO2006138669A3 (fr) Dispositif anatomique de type naturel pour tester l'injection de charges dans des tissus mous
WO2007091995A3 (fr) Matières fibreuses non tissées et électrodes réalisées à partir desdites matières
WO2009076141A8 (fr) Formulations d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
WO2006122825A3 (fr) 'nanobodies™' (nanocorps) perfectionnes pour traiter des troubles medies par une agregation
WO2006013202A3 (fr) Conjugaison de fvii
WO2007092091A3 (fr) Procedes de fabrication d'articles polymeres et leurs articles polymeres formes a l'aide des procedes
NO20035849L (no) Nye vevsfaktorrettede trombomodulinfusjonsproteiner som antikoagulanter
WO2008028117A3 (fr) Miméticorps glp-2, polypeptides, compositions, procédés et utilisations
WO2005113747A3 (fr) Systemes de culture tissulaire et organique multicellulaires
WO2002067812A3 (fr) Piece de membrane tympanique
WO2005123043A3 (fr) Formulations de sumatriptan absorbables au travers des membranes biologiques, et methodes de production et d'utilisation desdites formulations
WO2008071081A8 (fr) Préparation d'une protéine hybride anticoagulante provoquant un faible saignement et utilisation de cette dernière
WO2009086056A3 (fr) Bande de solin multicouche
WO2007067828A3 (fr) Mimétiques et polypeptides de glp-2, compositions, méthodes et utilisations
WO2007109155A3 (fr) dosages pour la detection d'anticorps anti enzymes lysosomales
WO2009046194A3 (fr) Produit d'étanchéité de fibrine
WO2008117746A1 (fr) Préparation de fibrinogène solide
WO2006036932A3 (fr) Sulfonamides et leurs utilisations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780046340.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07845883

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009540580

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007845883

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12519309

Country of ref document: US